These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21325411)

  • 1. Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies.
    Wu X; Changela A; O'Dell S; Schmidt SD; Pancera M; Yang Y; Zhang B; Gorny MK; Phogat S; Robinson JE; Stamatatos L; Zolla-Pazner S; Kwong PD; Mascola JR
    J Virol; 2011 May; 85(9):4578-85. PubMed ID: 21325411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.
    Doores KJ; Burton DR
    J Virol; 2010 Oct; 84(20):10510-21. PubMed ID: 20686044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1.
    Morgand M; Bouvin-Pley M; Plantier JC; Moreau A; Alessandri E; Simon F; Pace CS; Pancera M; Ho DD; Poignard P; Bjorkman PJ; Mouquet H; Nussenzweig MC; Kwong PD; Baty D; Chames P; Braibant M; Barin F
    J Acquir Immune Defic Syndr; 2016 Mar; 71(3):237-45. PubMed ID: 26413851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.
    Wibmer CK; Bhiman JN; Gray ES; Tumba N; Abdool Karim SS; Williamson C; Morris L; Moore PL
    PLoS Pathog; 2013 Oct; 9(10):e1003738. PubMed ID: 24204277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes.
    Hoffenberg S; Powell R; Carpov A; Wagner D; Wilson A; Kosakovsky Pond S; Lindsay R; Arendt H; Destefano J; Phogat S; Poignard P; Fling SP; Simek M; Labranche C; Montefiori D; Wrin T; Phung P; Burton D; Koff W; King CR; Parks CL; Caulfield MJ
    J Virol; 2013 May; 87(10):5372-83. PubMed ID: 23468492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.
    McLellan JS; Pancera M; Carrico C; Gorman J; Julien JP; Khayat R; Louder R; Pejchal R; Sastry M; Dai K; O'Dell S; Patel N; Shahzad-ul-Hussan S; Yang Y; Zhang B; Zhou T; Zhu J; Boyington JC; Chuang GY; Diwanji D; Georgiev I; Kwon YD; Lee D; Louder MK; Moquin S; Schmidt SD; Yang ZY; Bonsignori M; Crump JA; Kapiga SH; Sam NE; Haynes BF; Burton DR; Koff WC; Walker LM; Phogat S; Wyatt R; Orwenyo J; Wang LX; Arthos J; Bewley CA; Mascola JR; Nabel GJ; Schief WR; Ward AB; Wilson IA; Kwong PD
    Nature; 2011 Nov; 480(7377):336-43. PubMed ID: 22113616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.
    Pancera M; McLellan JS; Wu X; Zhu J; Changela A; Schmidt SD; Yang Y; Zhou T; Phogat S; Mascola JR; Kwong PD
    J Virol; 2010 Aug; 84(16):8098-110. PubMed ID: 20538861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
    Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
    J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.
    Pancera M; Shahzad-Ul-Hussan S; Doria-Rose NA; McLellan JS; Bailer RT; Dai K; Loesgen S; Louder MK; Staupe RP; Yang Y; Zhang B; Parks R; Eudailey J; Lloyd KE; Blinn J; Alam SM; Haynes BF; Amin MN; Wang LX; Burton DR; Koff WC; Nabel GJ; Mascola JR; Bewley CA; Kwong PD
    Nat Struct Mol Biol; 2013 Jul; 20(7):804-13. PubMed ID: 23708607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.
    Gift SK; Leaman DP; Zhang L; Kim AS; Zwick MB
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes.
    Das S; Boliar S; Mitra N; Samal S; Bansal M; Koff WC; Chakrabarti BK
    Retrovirology; 2016 Nov; 13(1):81. PubMed ID: 27871328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.
    Moore PL; Gray ES; Sheward D; Madiga M; Ranchobe N; Lai Z; Honnen WJ; Nonyane M; Tumba N; Hermanus T; Sibeko S; Mlisana K; Abdool Karim SS; Williamson C; Pinter A; Morris L;
    J Virol; 2011 Apr; 85(7):3128-41. PubMed ID: 21270156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody.
    Morales JF; Yu B; Perez G; Mesa KA; Alexander DL; Berman PW
    Mol Immunol; 2016 Sep; 77():14-25. PubMed ID: 27449907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance.
    Pritchard LK; Spencer DI; Royle L; Vasiljevic S; Krumm SA; Doores KJ; Crispin M
    J Virol; 2015 Jul; 89(13):6952-9. PubMed ID: 25878100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
    Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
    Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gp120 V5 Is Targeted by the First Wave of Sequential Neutralizing Antibodies in SHIV
    Jia M; Lu H; Kong XP; Cheng-Mayer C; Wu X
    Viruses; 2018 May; 10(5):. PubMed ID: 29772652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.